secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hims & Hers Health, Inc. (HIMS)
CIK:        0001773751
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001773751-24-000337
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hims & Hers Q3 rev $401.6M (+77% YoY), net income $75.6M, raises FY guidance
----------------------------------------------------------------------------

- Q3 2024: Revenue $401.6M (+77% YoY), net income $75.6M (vs -$7.6M), Adj EBITDA $51.1M.
- Subscribers 2.0M (+44% YoY); over 1M using personalized solutions; ex-GLP-1 sub growth 40% YoY.
- FY 2024 guidance raised: Revenue $1.460-1.465B, Adj EBITDA $173-178M.
- Weight loss offering: oral GLP-1 $100M annual run rate; 80K reports of supply shortage; planning liraglutide in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1773751/000177375124000337/0001773751-24-000337-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1773751/000177375124000337/hims-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001773751-24-000337

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer